Table 3.
End of study tumor and plasma concentrations of PF-309.
| CRC tumor model | % Growth inhibition | Tumor (ng/g)* | Plasma (ng/mL) | Tumor: plasma ratio* |
|---|---|---|---|---|
| CUCRC042 | 52 | 34.8 | 1.17 | 29.8 |
| 29.6 | 4.58 | 6.46 | ||
| Colo201 | 45 | 140.4 | 20.9 | 6.72 |
| 11.1 | 11.7 | 0.95 | ||
| GEO | 42 | 10.2 | 5.48 | 1.9 |
| 15.9 | 54.1 | 0.3 | ||
| 22.9 | 76.6 | 0.3 | ||
| CUCRC036 | 35 | 65.7 | 40.6 | 1.62 |
| 30.7 | 110 | 0.28 | ||
| 47.6 | 81.3 | 0.59 | ||
| CUCRC006 | 32 | 3.6 | 42.4 | 0.08 |
| 3.4 | 24.4 | 0.14 | ||
| CUCRC026 | 30 | 6.4 | 25.4 | 0.25 |
| 14.5 | 114 | 0.13 | ||
| 22.7 | 69.3 | 0.33 | ||
| 16.8 | 184 | 0.09 | ||
| HCT15 | 18 | 6.8 | 10.0 | 0.68 |
| 8.9 | 13.2 | 0.67 | ||
| 8.0 | 49.0 | 0.16 | ||
| CUCRC047 | −24 | 4.4 | 110 | 0.04 |
| 7.5 | 98.7 | 0.08 |
*p < 0.003 vs. % growth inhibition.